Showing 41 - 60 of 110
-
-
The CDC’s Test for Bird Flu Works, but It Has Issues
The Centers for Disease Control and Prevention promises better tests are being developed, but the episode points to vulnerabilities in the country’s defense against emerging outbreaks.
By Arthur Allen and Amy Maxmen -
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
By Arthur Allen Illustration by Oona Tempest -
Finland Is Offering Farmworkers Bird Flu Shots. Some Experts Say the US Should, Too.
Even with a stockpile of bird flu vaccinations, the federal government is not offering them to those at high risk. Along with testing and measures to prevent spread, vaccinations may protect people and stop the outbreak from becoming a pandemic.
By Amy Maxmen and Arthur Allen -
Bird Flu Tests Are Hard To Get. So How Will We Know When To Sound the Pandemic Alarm?
If widely used, flu tests could be helpful now. In the meantime, the government needs to clear a path for H5N1 tests, researchers warn, to avoid the early missteps of the covid pandemic.
By Amy Maxmen and Arthur Allen -
The Chicken and Egg Problem of Fighting Another Flu Pandemic
The spread of an avian flu virus in cattle has again brought public health attention to the potential for a global pandemic. Fighting it would depend, for now, on 1940s technology that makes vaccines from hens’ eggs.
By Arthur Allen -
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
By Arthur Allen -
Overdosing on Chemo: A Common Gene Test Could Save Hundreds of Lives Each Year
The FDA and some oncologists have resisted efforts to require a quick, cheap gene test that could prevent thousands of deaths from a bad reaction to a common cancer drug.
By Arthur Allen -
Why Covid Patients Who Could Most Benefit From Paxlovid Still Aren’t Getting It
Price worries, bureaucratic obstacles, and “I’m-over-covid-itis” slow uptake of a drug that’s complicated to take but often effective.
By Arthur Allen -
Patients See First Savings From Biden’s Drug Price Push, as Pharma Lines Up Its Lawyers
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
By Arthur Allen -
What the Health Care Sector Was Selling at the J.P. Morgan Confab
When bankers and investors flocked to San Francisco for the largest gathering of health care industry investors, the buzz was all about artificial intelligence, the next hit weight-loss drug, and new opportunities to make money through nonprofit hospitals.
By Molly Castle Work and Arthur Allen -
A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
By Arthur Allen -
-
Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, or PBMs, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.
By Arthur Allen -
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
By Arthur Allen -
Why the CDC Has Recommended New Covid Boosters for All
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it’s time for new boosters — and not only for those at highest risk of serious disease. Here are seven things you need to know.
By Arthur Allen -
Pfizer and Moderna Are Pushing the New Covid Booster. Should You Get It? The CDC Is About to Decide.
Chances are, if you aren’t older, chronically ill, or obese, you don’t need a forthcoming covid vaccine to stay out of the hospital. But it probably wouldn’t hurt.
By Arthur Allen -
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
-
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.
By Arthur Allen -
What You Need to Know About the Drug Price Fight in Those TV Ads
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
By Arthur Allen
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: